After several exploratory and confirmatory clinical trials, the intralesional administration of human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced diabetic foot ulcers (DFU). | Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers